CSF1R and glioblastoma: In order to achieve depletion of TAMs by CSF-1R, small molecule inhibitors and monoclonal antibodies were developed in the last decade with a few of them reaching clinical trials for the GBM treatment as monotherapy or in combination with other drugs [126,127].